Proposed policies would impose significant barriers and add burden for people with CF
Site Search
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Funding will support clinical trials for therapy that could help improve digestion in people with CF
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
Bipartisan legislation could help patients access necessary prescription drugs by potentially reducing the financial burden that results from complex and hard-to-navigate health insurance plans
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.